Compass Biotechnology, Inc. ("Compass") Appoints Thomas F. Krucker as President

PHOENIX, AZ, Jan. 12, 2012 /CNW/ - Compass Biotechnology's Board of Directors has appointed Thomas F. Krucker as President of Operations.

For the past five years, Mr. Krucker has been working in the investment banking industry and brings sophisticated financing, international operations, and market knowledge to Compass. Mr. Krucker's wide ranging and valuable expertise, from the automotive industry to the financial markets, will greatly assist in Compass' domestic and international sales efforts. Mr. Krucker has a J.D. from Pepperdine College of Law.

Mr. Krucker previously served with Toyota USA for 11 years and held national positions as IR Director and Import Director for the USA operations. During the course of his time with Toyota, his duties included oversight for five divisions which reported to him, including truck/rail transportation, ship routing, ten port authorities around USA, treasury/customs responsibility for company, insurance/claims, damage control for ocean rail vehicle delivery, truck assembly at all ports, accessory and preparation at all ports.

Dr. Joseph Sinkule, CEO of Compass, said, "Compass is excited to recruit someone with Tom's credentials as its President. Mr. Krucker has a proven track-record of performance in creating value in small- and mid-cap companies, and during his time with Toyota, was responsible for the largest selling region in USA and for building a dealer network for Toyota, which became the first imported vehicle nameplate to out-sell and out-register all domestic car lines including Chevrolet, Ford, and Chrysler. With international pharmaceutical product distribution and sales as our end goal, Tom should be able to contribute significantly to our current and future growth."

Garth Likes, Chairman of Compass stated, "Beyond his auto-industry expertise, Mr.Krucker has sophisticated finance and equity market knowledge and will be an invaluable asset to Compass Biotechnology, Inc."


Compass Biotechnologies, Inc. is a publically-traded specialty pharmaceutical company (COBI:OB) focused on building value in several key market areas - women's health, hepatitis anti-viral drugs and prophylactic vaccines, recombinant protein therapeutics called "biobetters", and cytokine reagents and growth factor supplements for the cell culture and biotech manufacturing industries. Products in these areas are being developed within business units or franchises with majority ownership held by Compass Biotechnologies, Inc.

Forward Looking Statements

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors.  Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.  Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.

SOURCE Compass Biotechnologies Inc.

For further information:

For further information and inquiries:

Compass Biotechnologies, Inc.

Dr. Joseph Sinkule
CEO and President
4105 N. 20th Street 
Suite 220 
Phoenix, AZ 85106 USA

Ph: 480.427.2026

Profil de l'entreprise

Compass Biotechnologies Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.